ImmunityBio, Inc. Common Stock
Symbol: IBRX (NASDAQ)
2.75
▼ (-3.68%) -0.105
Company Description:
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
Key Stats
- Today's Open: $2.85
- Today's High: $2.86
- Today's Low: $2.715
- Today's Volume: 20.00M
- Yesterday Close: $2.85
- Yesterday High: $2.97
- Yesterday Low: $2.79
- Yesterday Volume: 10.80M
- Last Min Volume: 2
- Last Min High: $2.745
- Last Min Low: $2.745
- Last Min VWAP: $2.745
Company Profile
- Name: ImmunityBio, Inc. Common Stock
- Website: https://www.immunitybio.com
- Listed Date: 2021-03-10
- Location: SAN DIEGO, CA
- Market Status: Active
- CIK Number: 0001326110
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $2.58B
- Round Lot: 100
- Outstanding Shares: 945.25M
- Asset Type: CS
RECENT FILINGS FOR IBRX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-08 | 8-K | View |
| 2025-08-05 | 10-Q | View |
| 2025-08-05 | 8-K | View |
| 2025-07-28 | 424B5 | View |
| 2025-07-25 | 8-K | View |
| 2025-06-23 | S-8 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 8-K | View |
| 2025-05-12 | 10-Q | View |
| 2025-05-12 | 8-K | View |
| 2025-05-05 | 8-K | View |
| 2025-04-30 | DEFA14A | View |
| 2025-04-30 | ARS | View |
| 2025-04-30 | DEF 14A | View |
| 2025-04-15 | 8-K | View |
| 2025-04-08 | 424B5 | View |
Latest News on IBRX